MBX Biosciences Financial Statements
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
53.24-0.01 (-0.02%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MBX Biosciences revenue and earnings
MBX Biosciences reported a net loss of $87.0 million, compared with a loss of $61.9 million a year earlier. Diluted earnings per share came in at -$2.38.
Summary generated from market data by MetaCap's automated system. Methodology
MBX Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Operating Expenses | 98.06M | 68.19M | 35.31M |
| Research & Development | 79.16M | 57.41M | 28.53M |
| Operating Income | -98.06M | -68.19M | -35.31M |
| Pretax Income | -87.00M | -61.90M | — |
| Income Tax | 0 | 0 | 0 |
| Net Income | -87.00M | -61.92M | -32.56M |
| Net Income growth (YoY) | — | — | — |
| EPS (Basic) | -2.38 | -5.82 | -31.96 |
| EPS (Diluted) | -2.38 | -5.82 | -31.96 |
| Shares Outstanding (Basic) | 36.51M | 10.64M | 1.02M |
| Shares Outstanding (Diluted) | 36.51M | 10.64M | 1.02M |
| EBITDA | -97.81M | -67.95M | -35.15M |
This table shows 3 annual periods of MBX Biosciences's income statement, from FY 2025 back to FY 2023, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MBX's reporting calendar. What is a income statement?